- Arch Biopartners (ARCH) is entering into an exclusive agreement with the University of Cincinnati to license new patent claims for its topical wound treatment
- The treatment, AB569, is designed to prevent, treat and heal burn and blast wound infections
- The treatment was designed at the University of Cincinnati
- The agreement builds on the existing license of AB569 Arch Biopartners has with the University of Cincinnati
- Arch Biopartners is up 2.40 per cent on the day, with shares of the company trading at C$1.28 at 11:01 am ET
Arch Biopartners (ARCH) is entering into an agreement to license new patent claims for its topical wound treatment.
The treatment, AB569, is designed to prevent, treat and heal burn and blast wound infections.
The treatment was designed at the University of Cincinnati.
It is meant to to target multi-drug resistant infections that are difficult to treat in the lungs, burn or blast wounds of soldiers, surgical incisions and diabetic skin ulcers.
The agreement builds on the existing license of AB569 that Arch Biopartners already has with the University of Cincinnati.
“With this new license, Arch now has a commercial path to develop the topical wound gel version of AB569 for clinical use. We look forward to exploring opportunities where Arch can support human trials targeting the prevention and treatment of antibiotic resistant infections in wounds,” said Arch Biopartners CEO Richard Muruve.
Burn or blast injuries are a major cause of morbidity and mortality, especially in the military. In some cases this is due to sepsis, which is often preceded by wound infection that delays wound healing.
A significant challenge in treating bacterial infections is their inherent or acquired antibiotic resistance. AB569 has been shown to kill multi-drug resistant (MDR) Gram-negative (G-) bacteria, according to the company.
Bacterial infections have historically been a major clinical challenge for both military and civilian health professionals, especially during the Iraq and Afghanistan conflicts. In combat medical care, acquired wound, burn, blast and ventilator-associated pneumonia infections, represent a formidable multi-drug resistant (MDR-AB) pathogen.
Arch Biopartners is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.
Arch Biopartners is up 2.40 per cent on the day, with shares of the company trading at C$1.28 at 11:01 am ET.